Search

Your search keyword '"Ponikowski P"' showing total 2,171 results

Search Constraints

Start Over You searched for: Author "Ponikowski P" Remove constraint Author: "Ponikowski P"
2,171 results on '"Ponikowski P"'

Search Results

1. Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes

2. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

5. Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study

6. Spot urine sodium‐to‐creatinine ratio surpasses sodium in identifying poor diuretic response in acute heart failure

11. Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement

12. The role of urine chloride in acute heart failure

13. Effectiveness of remote pulmonary artery pressure estimating in heart failure: systematic review and meta-analysis

14. Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study

15. Health-related quality of life and self-care in heart failure patients under telecare—insights from the randomized, prospective, controlled AMULET trial

18. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved

19. Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure

20. On directional convolution equivalent densities

21. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

22. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic

23. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

24. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic

26. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

28. RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers

29. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

30. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

32. Prognostic significance and clinical determinants of residual dyspnoea at discharge in acute heart failure: a single-centre, prospective observational study

33. Acute Heart Failure Is a Malignant Process: But We Can Induce Remission

34. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

35. Cognitive Decline Over Time in Patients With Systolic Heart Failure Insights From WARCEF

36. Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial

37. Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial

38. Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence

39. Clinical determinants and prognostic significance of hypocapnia in acute heart failure

40. The effects of P2Y12 adenosine receptors’ inhibitors on central and peripheral chemoreflexes

42. Association between mortality and implantable cardioverter‐defibrillators by aetiology of heart failure: a propensity‐matched analysis of the WARCEF trial

43. Clinical implications of low estimated protein intake in patients with heart failure

44. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

46. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

47. Impact of marathon performance on muscles stiffness in runners over 50 years old

48. Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

49. Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment

50. Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial)

Catalog

Books, media, physical & digital resources